GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 200 participants.
Also called NCT07613437
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT07613437
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China, Hong Kong SAR China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07613437. Randomized; no masking; primary purpose treatment. Start 2026-06-15 (anticipated); primary completion 2028-06-14 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial
- Acronym
- GLICH
- Condition
- Intracerebral Hemorrhage
- Intervention (Drug)
- Semaglutide, 0.5 mg/mL
- Lead sponsor
- Chinese University of Hong Kong
- Collaborator
- The First Affiliated Hospital of University of Science and Technology of China
- Collaborator
- First Affiliated Hospital of Wenzhou Medical University
Record details
- Record id
cardio:ct-nct07613437- Content hash
24f198c5bdc4a12e89ddc9947a7d58577d502b7b7a2606a40aa56a59d989e369